anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This invention discloses that a combination of two drugs, from two different and previously unrelated categories, provides effective and long-lasting relief from neuropathic pain. Both drugs can be taken orally, in a convenient, painless, non-invasive manner that does not require injections. One drug in this combination is an α2 adrenergic agonist, exemplified by clonidine. The other drug in the pain-relieving combination has a tri-cyclo-alkyl-amine (TCAA) structure. At least some TCAA drugs have antagonist (receptor-blocking) activity at two entirely different classes of neuronal receptors: the muscarinic subclass of acetylcholine (ACh) receptors, and the NMDA subclass of glutamate receptors. Such drugs include ethopropazine, normally used as an anti-cholinergic drug, and desipramine, normally used as an anti-depressant. Tests by the Applicants have shown that at least some TCAA drugs can relieve neuropathic pain to a limited extent, but at the doses required to relieve pain, they cause adverse side effects, and any pain relief is relatively brief and short-lived. However, when a TCAA drug such as ethopropazine is administered together with an α2 adrenergic agonist such as clonidine, these drugs mutually potentiate one another's neuropathic pain-relieving action, and provide potent and sustained neuropathic pain relief, even when each agent is administered at a low dosage that is below its threshold for causing adverse side effects. Accordingly, this drug combination can provide safe and effective relief of neuropathic pain and possibly other types of chronic and/or intractable pain, at dosages which are so low that they do not pose serious risks of adverse side effects.
The following adverse reactions have been identified during post-approval use of zileuton immediate-release tablets and may be applicable to zileuton extended-release tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship.   
Cases of severe hepatic injury have been reported in patients taking zileuton immediate-release tablets. These cases included death, life-threatening liver injury with recovery, symptomatic jaundice, hyperbilirubinemia, and elevations of ALT >8xULN.   
Cases of sleep disorders and behavior changes have also been reported [see Warnings and Precautions ( 5.2.) ].
AIM: The aim of this case report is to present the case of a patient with iatrogenic Kaposi's sarcoma afflicting several organs, ocular manifestation.
CASE REPORT: In a 74-year-old kidney transplant patient receiving immunosuppressive therapy, iatrogenic Kaposi's sarcoma (KS) developed in both lower eyelids. Subsequently, KS was confirmed in the region of the left forearm, with suspicion of lesions in the lungs. The ocular tumor was surgically removed with negative margins, requiring no further therapy. The lesion on the left forearm was completely excised. The patient underwent radiotherapy for the lung lesions, and immunosuppressive therapy was reduced.
CONCLUSION: The case highlights the importance of early identification of KS, its histological verification, radical resection, and multidisciplinary collaboration. Knowledge of the epidemiology of this condition is a key factor in determining the correct diagnosis.
OBJECTIVES: The objective of this study was to synthesise the evidence of older persons' experiences of frailty.
BACKGROUND: The world's population is ageing with those aged over 60 years expected to total 2 billion by 2050. Although not exclusive to ageing, there is a higher prevalence of frailty in older adults, with corresponding demand for related healthcare. While definitions of frailty are debated, there is emerging consensus that sole reliance on biomedical conceptualisations is inadequate to capture the complex needs of older persons living with frailty. In addition, the voices of older persons have largely been excluded from frailty discourses. There is a consequent need for an expanded approach.
METHODS: A meta-synthesis was conducted of the literature on older persons' experiences of frailty. CINAHL, Medline, Embase and ASSIA databases were systematically searched up to January 2024. Reference lists of retrieved sources and grey literature were also searched. Studies were independently evaluated for inclusion by two reviewers using predetermined inclusion criteria. Included studies were quality appraised using a standardised tool, and extracted data were thematically analysed and synthesised.
RESULTS: Eight hundred and thirteen studies were identified as potentially relevant. Following title and abstract review, 52 studies were selected for full-text review. Thirty-four studies were subsequently excluded as they did not address the systematic review question, leaving 17 included in the final review. An additional two studies were identified via grey literature sources. Older persons' experiences of frailty were synthesised with reference to three themes: (i) living with frailty: a multidimensional experience; (ii) living with frailty: acceptability and associations; and (iii) living with frailty: resisting and adapting and losing control.
CONCLUSIONS: Older persons' experiences of frailty revealed a resistance to the biomedical use of the term generally used in clinical practice. Instead, a more nuanced and multidimensional understanding of frailty was identified in the experiences of older persons.
IMPLICATIONS FOR PRACTICE: Health and social care personnel should therefore consider an expanded approach in practice that incorporates the perspective of older people who strive to maintain independence and control when living with frailty. Doing so may enhance shared understanding and person-centred care planning between older persons and professionals.
Neuroscience dogma avers that astrocytic "scars" inhibit axonal regeneration after spinal cord injury (SCI). A recent report suggested however that astrocytes form "borders" around lesions that are permissive rather than inhibitory to axonal growth. We now provide further evidence supporting a facilitatory role of astrocytes in axonal regeneration after SCI. First, even 6months after SCI, injured axons are retained within regions of densely reactive astrocytes, in direct contact with astrocyte processes without being repelled. Second, 6 month-delayed implants of neural stem cells extend axons into reactive astrocyte borders surrounding lesions, densely contacting astrocyte surfaces. Third, bioengineered hydrogels implanted into sites of SCI re-orient reactive astrocytic processes to align along the rostral-to-caudal spinal cord axis resulting in successful regeneration into the lesion/scaffold in close association with astrocytic processes. Fourth, corticospinal axons regenerate into neural progenitor cells implanted six months after injury in close association with host astrocytic processes. Thus, astrocytes do not appear to inhibit axonal regeneration, and the close association of newly growing axons with astrocytic processes suggests a facilitatory role in axonal regeneration.
PROBLEM TO BE SOLVED: To obtain the subject liquid medicine containing taurine and an isomerized sugar and capable of reducing the browning of the liquid medicine. SOLUTION: This liquid medicine contains taurine and an isomerized sugar having an ash content of <=0.001wt.%. The taurine and the isomerized sugar are compounded in amounts of 0.02-4W/V% and 5-40W/V%, subsequently, based on the whole amount of the liquid medicine, and the liquid medicine is preferably controlled to a pH of 2-6 from the view point of flavor. A sweetener such as sucrose may be compounded for the improvement of a taking touch. The liquid medicine may further suitably be compounded with conventional vitamins, their derivatives, amino acids, galenicals, caffeine, royal jelly, a polyhydric alcohol, a perfume, a preservative, etc. Although liquid medicines containing an amino acid such as taurine and a sugar such as sucross are generally brown, the liquid medicine is not brown, even when an isomerized sugar is added.
The iCBT platform selected for use in this study (Sanvello™) is an evidence-based mobile app created by clinical experts that has been shown to decrease depression, anxiety, and stress and to increase self-efficacy in a non-IBD population.15 App features include: daily mood tracking; guided journeys (e.g. psychoeducational content providing background information about cognitive behavioral therapy and instructing users on how to use app tools to maintain motivation and interest); coping tools (e.g. meditation, goal setting, and negative thought redirecting activities); weekly progress assessments; community support board.
The present disclosure discloses method and a critical event managing system for managing time-critical events associated with critical devices. The critical event managing system identifies time-critical events from plurality of events based on predetermined factors related to the plurality of events. The plurality of events is determined from first procedural sequences identified from procedural narration by a practitioner and stored protocol manual. At least one of missed and incorrect events are determined based on comparison between reference and observed values associated with critical devices. A revised execution plan is provided iteratively based on historical data, data provided by practitioner, first procedural sequences, and metadata associated with plurality of parameters. The missed and incorrect events are executed as second procedural sequences based on revised execution plan, thereafter, outcome from execution of first procedural sequences and second procedural sequences is combined in order to manage time-critical events associated with critical devices.
A system and method for providing health care services including a health care insurance plan to one or more associations are presented. The invention includes a parent management company organized to manage general operations, provide a health care service, and provide an operational process. The parent management company organizes an association health component as a subsidiary of the association and trains the personnel of the association health component. The parent management company also provides the services of a wellness component, a risk management component, a financial services component, and a data management component. A managing general agent licenses the operational process and manages the operational process for the association health component. The association health component may franchise the health care service and the operational process to additional associations and association health components. The invention further provides access to the services through an Internet component. In one embodiment, the invention also provides a point of service component with identification and billing services.
Aims and objectives: This study aims to examine the effects of the body-mind-spirit group therapy on marital close relationships, sleeping quality, depression, quality of life, meaning of life, and salivary cortisol levels in metastatic breast cancer survivors and partners. Methods: The design adopts the randomized controlled trial (RCT). The metastatic breast cancer survivors will be recruited from outpatient department of surgical at hospital. The partners will be invited to participate in this study through the survivors. The 120 dyad survivors and spouse will be randomly assigned into an experimental group or a control group. Survivors and spouse partners in an experimental group will receive 2 months time body-mind-spirit group therapy while those in a control will receive usual care in the same period of time. The outcome measures include Experiences in close relationships scale, Moss sleeping scale, Short-form 12 health-related quality of life questionnaires, Meaning of life questionnaire, BDI-II depression scale and salivary cortisol levels. Measurement time-points include pre intervention, post intervention (after 8 weekly group therapy), \& then 3, 6, 12 months after the end of intervention for the maintenance effect. Univariate analyses will be performed to explore the basic characteristics of participants. The hierarchical linear model will be used to test the hypothesis the improvement is higher in intervention group than the control group in the effects of marital close relationships, sleeping quality, depression, meaning of life, quality of life, and salivary cortisol levels in metastatic breast cancer survivors and partners.
Transient receptor potential canonical 3 (TRPC3) channels are important in regulating Ca2+ homeostasis and have been implicated in the pathophysiology of chemically induced seizures. Inherited seizure susceptibility in genetically epilepsy-prone rats (GEPR-3s) has been linked to increased voltage-gated Ca2+ channel currents in the inferior colliculus neurons, which can affect intraneuronal Ca2+ homeostasis. However, whether TRPC3 channels also contribute to inherited seizure susceptibility in GEPR-3s is unclear. This study investigated the effects of JW-65, a potent and selective inhibitor of TRPC3 channels, on acoustically evoked seizure susceptibility in adult male and female GEPR-3s. These seizures consisted of wild running seizures (WRSs) that evolved into generalized tonic-clonic seizures (GTCSs). The results showed that acute administration of low doses of JW-65 significantly decreased by 55-89% the occurrence of WRSs and GTCSs and the seizure severity in both male and female GEPR-3s. This antiseizure effect was accompanied by increased seizure latency and decreased seizure duration. Additionally, female GEPR-3s were more responsive to JW-65's antiseizure effects than males. Moreover, JW-65 treatment for five consecutive days completely suppressed acoustically evoked seizures in male and female GEPR-3s. These findings suggest that inhibiting TRPC3 channels could be a promising antiseizure strategy targeting Ca2+ signaling mechanisms in inherited generalized tonic-clonic epilepsy.
The present invention relates to a system and a method for controlling the attribute of a user interface (UI) by data. In the present invention, an application program is divided into an independent part, a logical part and a UI part, wherein the logical part operates the data values in the application program; the UI part is in charge of displaying the UI attribute. A binding specification describes the relationship between the UI attribute and the data values. When the data values experience change, a system level code uses the binding specification to determine the informed method and determine the method for guiding the UI part to reflect the change in the UI attribute. The binding specification determines a source data item, a path to the data values in the source data item, a target UI element, and the UI attribute on the target user element. Codes or a sign language can be used to specify the binding.
The invention discloses a medicine molecule having selective anticancer activity. The structure is shown in the formulation (1); the invention is characterized in that chiral organic diamine is connected with small molecules or biological big molecules to form hydrogen-substituted derivative of the ammonia. The invention also discloses a preparation method for preparing typical compound and the inhibitive effect as well as other effect mechanisms of the compound for the growth of breast cancer and cancer cells of human. In the formulation, N-N indicates one random substituted, un-substituted chiral organic diamine. A1 and A2 can be selected from one organic group or small-molecule compound. N-N, A1 and A2 can be further connected with the biological big molecule. The A1 and A2 are not hydrogen at the same time.
A palatable, oral compsn for treatment of psoriasis, which is easy to measure out, consists of >=1 fumaric acid cpd. (I) diluted with the acid alkali salts of tartaric citric and ascorbic acid, and with MgSO4 and sugar, and is administered dissolved in water. (I) is fumaric acid itself; its neutral or acid salts:di- or mono-esters or their salts including Mn salts. Also new are topical (I)-based compsns. applied together with the acid salts of tartaric and citric acids and opt. with Vitamin A acid. The compsns. quickly normalise the metabolic status in cases of psoriasis and also improve circulatory disorders and senile diabetes, and normalise cholesterol levels. The solns. have an acceptable baste, are readily accepted by children and alleviate gastric and intestinal disorders from which many psoriasis patients suffer. A compsns. for adding to bathing water comprises (wt. pts.) fumaric acid 100; dimethyl fumarate 100; tartaric acid 100; K or NaHCO3 150; citric acid 50. 2-5 Teaspoons are added to the bath.
One of the properties of human breast cancer cells is cancer stemness, which is characterized by self-renewal capability and drug resistance. Protein kinase D1 (PRKD1) functions as a key regulator of many cellular processes and is downregulated in invasive breast cancer cells. In the present invention, it was found that PRKD1 was upregulated in MCF-7-ADR human breast cancer cells characterized by drug resistance. Additionally, the present inventors have found that PRKD1 expression was negatively regulated by miR-34a binding to the PRKD1 3-UTR. PRKD1 expression increased following performance of a tumorsphere formation assay in MCF-7-ADR cells. The present inventors also found that reduction of PRKD1 by ectopic miR-34a expression or PRKD1 siRNA treatment resulted in suppressed self-renewal ability in breast cancer stem cells. Furthermore, the present inventors have confirmed that the PRKD1 inhibitor CRT0066101 reduced phosphorylated PKD/PKC, leading to suppression of breast cancer stemness through GSK3/-catenin signaling. PRKD1 inhibition also influenced apoptosis initiation in MCF-7-ADR cells. Tumors from nude mice treated with miR-34a or CRT0066101 showed suppressed tumor growth, proliferation, and induced apoptosis. These results provide evidence that regulation of PRKD1, a novel miR-34a target, can contribute to overcoming cancer stemness and drug resistance in human breast cancer.
The multinodular and vacuolating neuronal tumor (MVNT) is a recently recognized brain lesion. MVNT has a characteristic appearance in MRI images and is potentially epileptogenic. To the best of our knowledge, no report has yet described this pathological entity in the forensic medicine literature. We present two medicolegal autopsy cases where postmortem MRI (PMMR) was useful to detect this lesion. Case 1: a man in his 30s, with about a 7-year history of intractable epilepsy and known MVNT died suddenly. Although MVNT was not detected in the initial morphological evaluation during autopsy, PMMR of the formalin-fixed brain revealed the lesion in the left frontal lobe. Histopathology confirmed it as a MVNT. Case 2: a man in his 20s hanged himself to death. PMMR prior to autopsy revealed MVNT in his brain, and the diagnosis was confirmed by a detailed histopathological evaluation. In both cases, postmortem CT was not useful for evaluation. The cases suggested that MVNT can cause sudden, unexpected epileptic death, and pre- or post-autopsy PMMR may be useful to detect it.
After participants are enrolled, they would be given medical nutrient treatment. Besides, they need have a follow-up visit every two weeks. Blood glucose, body weight, lifestyle and clinical information are collected. Blood samples and stool samples are collected in 28 and 32 pregnant weeks, respectively.
Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Directions for Use: Fill dosage cup to the fill line (15 mL). Swish in your mouth undiluted for 30 seconds, then spit out. Use after breakfast and before bedtime. Or, use as prescribed by your dentist.

Note: To minimize medicinal taste, do not rinse with water immediately after use.

Rx Only.

Keep Out Of Reach Of Children.﻿
PURPOSE: Sickle cell patients presented with progressive hip pain and limitation of daily activities, as evidenced by low preoperative hip scores and failed conservative therapy. Management of femoral head avascular necrosis (AVN) using total hip replacement (THR) in sickle cell disease (SCD) is widespread in developed countries, but it is still in its initiation stage in developing countries. The outcome of using cementless THR among SCD patients is still unknown with lack of published studies from regional countries. This study aimed to evaluate the outcome of using cementless primary THR among patients with sickle cell disease with end-stage hip avascular necrosis in Yemen.
METHODS: Thirty cementless primary total hip arthroplasty (THA) were performed for AVN of the femoral head in 27 sickle cell patients, at Al.-Thawra Modern General Hospital-Sana'a, Yemen, from January 2018 to December 2022.
RESULTS: The mean age of the patients was 27 ± five years (ranged 18-37 years) with a male to female ratio was 3:1. Steinberg staging for hip AVN was stage IV, one patient (3%); stage VI, thirteen patients (45%); and stage V, sixteen patients (51%). THR was on right side 14 (52%), left side 10 (37%), and bilateral 3 (11%). The implant used was ceramic on polyethylene acetabular liner. All patients showed improvement in Harris hip score from preoperative mean hip score was 25 ± 8 points to postoperative mean hip score was 88 ± 6 points at the last follow-up. Mean of the length of stay in hospital was 12.7 ± eight days (ranged from 4 to 32 days); the mean operating time was 107 ± 23 min. Three cases had superficial wound infection; four patients had five intraoperative fractures; two cases had pulmonary complications; one case had abdominal crisis. All patients had postoperative leg length discrepancy less than 2 cm. None had deep infection, nerve injury, wound hematoma, aseptic loosing, dislocation, DVT, heterotopic ossification, or death.
CONCLUSION: THR in SCD has a good outcome using cementless THA with a low rate of complication in Yemen, a developing country.
An embodiment in accordance with the present invention provides a non-invasive solution to risk stratify the risk of arrhythmia in patients with TOF. Currently, no reliable method for non-invasive risk stratification exists. In the realm of congenital heart disease, cardiac MRI is now used routinely for patients with Tetralogy of Fallot (TOF), the most common form of cyanotic congenital heart disease. An innovative platform for using clinical MRI data to create 3D electromechanical models of the heart enables predictions of whether or not patients with ischemic heart disease have the substrate for arrhythmia and what their relative risk for such an event is. An embodiment of the current invention provides a non-invasive solution to risk stratify the risk of arrhythmia in patients with TOF. Currently, no reliable method for non-invasive risk stratification exists.
Part 1: Randomized, double blind, placebo controlled dose-finding. Patients will be assigned to 1 of 3 doses OligoG, or to placebo, on top of Standard of Care. Patients will be treated for 12 weeks, followed by 4 weeks washout.The primary endpoint is relative change in % predicted FEV1. Secondary endpoints include additional spirometry parameters, exacerbation rate, Quality of Life, sputum rheology and microbiology, safety laboratory tests and adverse event reporting.

Part 2: Randomized double-blind 6 -month study, for longer term follow-up of the dose identified in Part 1. New patients will be recruited in part 2, in addition to patients who received placebo in Part 1. In addition to the endpoints studied in Part 1, Part 2 will include Lung Clearance Index (LCI), chest imaging by MRI or CT, and pharmaco-economic parameters.